TheraRadar
Clinical-Stage Companies / Praxis Precision

Praxis Precision

Pre-Approval PRO BETA
16
Total Trials
8
Phase 3
10
Phase 2
7
Recruiting
226
Score

Pipeline by Phase

Phase 3
8
Phase 2
10
Phase 1
2

Therapeutic Focus

Essential Tremor SCN2A Encephalopathy Focal Seizure Major Depressive Disorder Focal Epilepsy

Clinical Trials (16)

NCT07505004 Phase 3 RECRUITING

Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures

Started: 1/29/2026

NCT07010471 Phase 3 RECRUITING

A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine

Started: 7/9/2025

NCT07019922 Phase 3 RECRUITING

A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety

Started: 8/13/2025

NCT07287163 Phase 3 ENROLLING BY INVITATION

Clinical Trial of Vormatrigine in Adult Patients With Epilepsy

Started: 10/27/2025

NCT06087276 Phase 3 ENROLLING BY INVITATION

Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)

Started: 11/2/2023

NCT06999902 Phase 2 RECRUITING

Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)

Started: 12/11/2024

NCT06908356 Phase 2 RECRUITING

An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures

Started: 1/10/2025

NCT05818553 Phase 2 ACTIVE NOT RECRUITING

A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)

Started: 8/2/2023

NCT05021991 Phase 2 COMPLETED

A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor

Started: 10/14/2021

NCT05021978 Phase 2 COMPLETED

A Clinical Trial of PRAX-944 in Participants With Essential Tremor

Started: 3/3/2020

NCT05260541 Phase 2 TERMINATED

A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder

Started: 1/25/2022

NCT05387642 Phase 2 WITHDRAWN

A Clinical Trial of PRAX-114 in Participants With Essential Tremor

Started: 4/5/2022

NCT04969510 Phase 2 COMPLETED

A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive Disorder

Started: 6/24/2021

NCT04832425 Phase 2 COMPLETED

A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder

Started: 3/30/2021

NCT05737784 Phase 1 RECRUITING

A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy

Started: 4/13/2023

NCT06840925 Phase 1 NOT YET RECRUITING

A Clinical Trial to Evaluate the Relative Bioavailability of PRAX-628

Started: 3/24/2025

Drug Candidates

40 mg/day vormatrogine for 12 weeks 30 mg/day vormatrogine for 12 weeks 20 mg/day vormatrogine for 12 weeks Placebo PRAX-562 1.0mg/kg/day PRAX-562 1.5mg/kg/day PRAX-562 vormatrogine 1mg elsunersen 0.5mg elsunersen
Activity Status: Active
Last Trial Started: 1/29/2026
Last Trial Ended: 2/29/2024
Trials (12 months): 4
Completed Trials: 4
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.